WilmerHale Counsels Merrimack in $25M Debt Facility

WilmerHale Counsels Merrimack in $25M Debt Facility

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
We guide clients through today’s ever-changing debt markets, representing them in a broad variety of debt deals that range from complex financial structures to traditional loan transactions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a clinical-stage oncology company focused on biomarker-defined cancers, announced on July 2, 2018, the closing of a $25 million term loan with Hercules Capital (NYSE:HTGC), $15 million of which was funded at closing. Merrimack's funds are projected to help the company's planned operations into the first quarter of 2020.

The WilmerHale team representing Merrimack is led by Jamie Class, and includes John Sigel and Brandt Tierney.

Read Merrimack’s press release regarding the financing.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel